Full Press Release Details
Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference.
ZYME
Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference
Key Takeaway: Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference
Price reaction · baseline $18.89 (2025-11-03 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
day 0 close · peak
-3.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers